Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | XL092 |
Synonyms | |
Therapy Description |
XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XL092 | XL-092|XL 092|Zanzalintinib | MET Inhibitor 57 VEGFR Inhibitor (Pan) 35 | XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | ITA | ESP | BEL | AUT | AUS | 4 |
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 2 |